Clozapine treatment in the early stages of schizophrenia.

PURPOSE OF REVIEW Clozapine is the most effective treatment for antipsychotic nonresponse, yet its use in the early stages of schizophrenia remains substantially delayed. Because the first several years after diagnosis represent a critical window for influencing long-term outcomes, clarifying the benefits, risks, and implementation challenges of earlier clozapine initiation is both timely and clinically relevant. This review synthesizes recent evidence on clozapine effectiveness, safety, and utilization within the first five years of illness. RECENT FINDINGS Across cohort studies, registry analyses, and meta-analyses, clozapine demonstrates superior response and relapse-prevention outcomes when used following early treatment failure or relapse. Sequential treatment data show diminishing returns with repeated nonclozapine antipsychotic trials, whereas clozapine maintains comparatively higher response rates. Earlier initiation, particularly within three years of first episode, is associated with improved negative symptoms and functioning. Despite these advantages, clozapine remains markedly underutilized, with substantial delays. Safety profiles in first episode and early-phase samples mirror established risks, with serious adverse events uncommon in the short term. SUMMARY Evidence supports considering clozapine earlier in the treatment sequence for early-stage schizophrenia, particularly after initial nonresponse or relapse. System-level interventions and emerging biomarker-guided strategies may reduce delays and improve long-term outcomes.

• Publication year

  2026

• Venue

  Current Opinion in Psychiatry

• Publication date

  2026-01-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/YCO.0000000000001059PMID 41778374PMCID PMC13034744
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparative effectiveness of antipsychotic treatment strategies for relapse prevention in first-episode schizophrenia in Finland: a population-based cohort study

  2025cited by this paper
• Comparative efficacy and safety of Clozapine vs. Quetiapine in schizophrenia and related disorders: An updated systematic review.

  2025cited by this paper
• Trends and cross-country inequalities in schizophrenia from 1990 to 2021, with prediction to 2035: a systematic analysis of the global burden of disease study 2021

  2025cited by this paper
• Association of relapse with all-cause mortality in adult patients with stable schizophrenia

  2025cited by this paper
• Response rates to sequential trials of antipsychotic medications according to algorithms or treatment guidelines in psychotic disorders. A systematic review and meta-analysis.

  2024cited by this paper
• Clozapine Use in the First Two Years after First-Episode Psychosis in a Real-World Clinical Sample.

  2024cited by this paper
• Long-Term Course of Remission and Recovery in Psychotic Disorders.

  2024cited by this paper
• Umbrella Review: Early-Onset Psychosis: Atlas of the Meta-Analytical Evidence.

  2024cited by this paper
• Long-term outcomes of delayed clozapine initiation in treatment-resistant schizophrenia: a multicenter retrospective cohort study

  2023cited by this paper
• Influence of time to clozapine prescription on the clinical outcome.

  2023cited by this paper
• The Impact of Clozapine Delay on Clinical Outcomes in Schizophrenia.

  2023cited by this paper
• Clinical and treatment predictors of relapse during a three-year follow-up of a cohort of first episodes of schizophrenia.

  2022cited by this paper
• Naturalistic study on the use of clozapine in the early phases of non-affective psychosis: A 10-year follow-up study in the PAFIP-10 cohort.

  2022cited by this paper
• OUP accepted manuscript

  2021cited by this paper
• HLA-DQB1 6672G>C (rs113332494) is associated with clozapine-induced neutropenia and agranulocytosis in individuals of European ancestry

  2021cited by this paper
• A neuroimaging biomarker for striatal dysfunction in schizophrenia

  2020cited by this paper
• The critical treatment window of clozapine in treatment-resistant schizophrenia: Secondary analysis of an observational study.

  2017cited by this paper
• Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia

  2016cited by this paper
• Baseline Striatal Functional Connectivity as a Predictor of Response to Antipsychotic Drug Treatment.

  2015cited by this paper
• Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.

  2013cited by this paper
• Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain.

  2012cited by this paper
• Genetic association study between antipsychotic-induced weight gain and the melanocortin-4 receptor gene

  2012cited by this paper
• Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder.

  2004cited by this paper
• Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder.

  1999cited by this paper
• Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

  1988cited by this paper

• No citing papers are available for this paper.